NASDAQ · CTOR
Healthcare · Drug Manufacturers - General
$0.55
Up+$0.02 (+4.63%)
Updated Nov 2, 2026, 6:17 AM
SID Score
3.5/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · CTOR
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 30, 2026
CTOR closed at $0.55 after 20 trading sessions, down 36.58% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 30, 2026 | $0.5274 | $0.5653 | $0.5001 | $0.554 | 292.79K |
| Oct 29, 2026 | $0.58 | $0.6074 | $0.5004 | $0.5295 | 195.08K |
| Oct 28, 2026 | $0.6285 | $0.6285 | $0.5712 | $0.5768 | 96.01K |
| Oct 27, 2026 | $0.634 | $0.6455 | $0.571 | $0.611 | 134.94K |
| Oct 26, 2026 | $0.627 | $0.6893 | $0.539 | $0.5957 | 885.29K |
| Oct 23, 2026 | $0.72 | $0.72 | $0.51 | $0.5795 | 70.53K |
| Oct 22, 2026 | $0.729 | $0.73 | $0.6554 | $0.6995 | 38.02K |
| Oct 21, 2026 | $0.705 | $0.76 | $0.6523 | $0.7003 | 22.89K |
| Oct 20, 2026 | $0.73 | $0.7467 | $0.6601 | $0.671 | 97.44K |
| Oct 19, 2026 | $0.7562 | $0.7599 | $0.70 | $0.7104 | 40K |
| Oct 16, 2026 | $0.7699 | $0.7699 | $0.75 | $0.7679 | 11.71K |
| Oct 15, 2026 | $0.76 | $0.7699 | $0.7451 | $0.746 | 11.06K |
| Oct 14, 2026 | $0.811 | $0.811 | $0.75 | $0.7836 | 27.57K |
| Oct 13, 2026 | $0.80 | $0.8435 | $0.7425 | $0.792 | 96.91K |
| Oct 12, 2026 | $0.8598 | $0.8598 | $0.7798 | $0.8126 | 67.96K |
| Oct 9, 2026 | $0.842 | $0.8799 | $0.80 | $0.8398 | 71.05K |
| Oct 8, 2026 | $0.87 | $0.87 | $0.8201 | $0.835 | 56.58K |
| Oct 7, 2026 | $0.8469 | $0.9013 | $0.8469 | $0.851 | 105.51K |
| Oct 6, 2026 | $0.858 | $0.9199 | $0.8121 | $0.85 | 109.84K |
| Oct 5, 2026 | $0.93 | $0.93 | $0.8601 | $0.8735 | 85.51K |
The latest Smart Investors Daily articles mentioning CTOR.
Company
Market Activity
Research & News
CTOR research
Company profile and research snapshot.
Citius Oncology Inc is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products targeting unmet needs with a focus on oncology products. In addition, Citius completed enrollment in its Phase 2b trial of CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 23, 2025 | Maxim Group | Buy | — |
| May 23, 2025 | Maxim Group | Hold | — |
| Nov 27, 2024 | Maxim Group | Buy | — |
| Aug 13, 2024 | EF Hutton | Buy | — |
No generated briefing is available yet.
Benzinga · Sep 18, 2026
Gainers DataMEDS AI (NASDAQ:MEDS) shares increased by 12.9% to $4.24 during Friday's after-market session. The market value of their outstanding shares is at $14.8 million. Geovax Labs (NASDAQ:GOVX) stock rose
Yahoo · Sep 3, 2026
Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced that Chairman and Chief Executive Officer Leonard Mazur will present and host one-on-one investor meetings at two upcoming investor conferences in New York City.
Benzinga · Aug 14, 2026
Citius Oncology (NASDAQ:CTOR) reported quarterly losses of $(0.08) per share which met the analyst consensus estimate. This is unchanged from the same period last year. The company reported quarterly sales of $1.494
Yahoo · Aug 12, 2026
Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), an oncology-focused biopharmaceutical company and majority-owned subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), today announced that its Board of Directors voted to appoint Jonathan Peri, Ph.D., J.D., as an additional independent director, effective August 10, 2026. Following a unanimous vote of approval by the Board, the appointment expands the Company's Board of Directors to nine members.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning CTOR.
